Last reviewed 2026-04-23 · How we verify

TAK-667

TAK-667 is a CD47 antibody that works by blocking the interaction between CD47 and SIRPα on macrophages, thereby promoting phagocytosis of tumor cells.

TAK-667 is a CD47 antibody that works by blocking the interaction between CD47 and SIRPα on macrophages, thereby promoting phagocytosis of tumor cells. Used for Relapsed or refractory multiple myeloma.

At a glance

Mechanism of action

By blocking the CD47-SIRPα interaction, TAK-667 enhances the ability of macrophages to recognize and engulf tumor cells, leading to their destruction. This mechanism is thought to be particularly effective in the context of hematologic malignancies, where tumor cells often express high levels of CD47.

Approved indications

• Relapsed or refractory multiple myeloma

Common side effects

• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.